Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Phase II \& Phase III: This is a pragmatic, adaptive, randomized, multicenter phase II/III study evaluating IFX-1 for the treatment of COVID-19 related severe pneumonia. The study consists of two parts: Phase II, an open-label, randomized, 2-arm phase evaluating best supportive care (BSC) + IFX-1 (Arm A) and BSC alone (Arm B); and Phase III, a double-blind, placebo-controlled, randomized phase comparing standard of care (SOC) + IFX-1 (Arm A) versus SOC + placebo-to-match (Arm B)
Epistemonikos ID: 9f58727dac205180a22f26bc63a618bafa73849e
First added on: Apr 06, 2020